发布时间: 2026 - 01 - 31
Preface:In January, the "Spring Festival Gala" of the global biopharmaceutical industry – the 44th Annual J.P. Morgan Healthcare Conference – was held grandly in San Francisco, USA. Efung Capital's portfolio companies, including Ascentage Pharma, Hangzhou Gaoguang, Andao Pharma, Biao Xin Bio, and Mai Lian Ke, made major appearances, collectively showcasing the cutting-edge power of Chinese innovative drug companies.Efung's portfolio companies also achieved continuous breakthroughs in key areas such as clinical trials, regulatory approvals, and collaborations, outlining a clea...
浏览次数:0
发布时间: 2022 - 08 - 05
Just recently, the Hong Kong Stock Exchange welcomed the successful submission of the first share of the new crown oral drug. On August 4, the Hong Kong Stock Exchange disclosed that Henan Zhenzhen Biotechnology Co., Ltd. (hereinafter referred to as 'Genuine Biotech') submitted a listing application to the Hong Kong Stock Exchange. Efung Capital is the only investment institution to accompany the growth of Genuine Biotech, and it has led two consecutive rounds of investment for the company. The first was in November 2020, when it exclusively led the series A financing of Genu...
浏览次数:5688
发布时间: 2022 - 08 - 10
On August 9, the National Health Commission issued a notice, according to the approval opinions of the State Food and Drug Administration on the application for registration of additional indications for the treatment of novel coronavirus pneumonia with azvudine tablets. In order to further improve the antiviral treatment scheme for novel coronavirus pneumonia, the drug was included in the diagnosis and treatment scheme for novel coronavirus pneumonia (Ninth Edition) through research. The details are as follows:1、 Drug name: Azivudine  2、 Indications It is used to treat adu...
浏览次数:4602
发布时间: 2022 - 08 - 01
Recently, Apexigen, a portfolio company of Efung Capital, and Brookline Capital Acquisition Corp.-a Special Purpose Acquisition Company (SPAC)-entered an official merger process, resulting that Brookline Capital Acquisition Corp. was renamed to Apexigen, Inc. Guided and led by Dr. Xiaodong Yang, president as well as Chief Executive Officer (CEO) of Apexigen company, the firm joined the listing of Nasdaq successfully and presented in stock code “APGN” this evening, August 1st, Beijing time. In July 2018, Efung Capital was one of the players of Apexigen's Series C financing.Headquartere...
浏览次数:530
17页次4/5首页PREV12345NEXTlast page
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务